These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1673757)
1. Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII. Montoro JB; RodrÃguez S; Altisent C; Tusell JM Lancet; 1991 May; 337(8751):1222. PubMed ID: 1673757 [No Abstract] [Full Text] [Related]
2. Transient inhibitor to monoclonal antibody-purified factor VIII concentrate. Votaw ML; Miller S Am J Hematol; 1992 Dec; 41(4):297. PubMed ID: 1288295 [No Abstract] [Full Text] [Related]
3. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor]. Klukowska A; Zieleniewska B Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036 [TBL] [Abstract][Full Text] [Related]
4. The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A. Aronson DL Transfusion; 1990 Oct; 30(8):748-58. PubMed ID: 2120808 [No Abstract] [Full Text] [Related]
5. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII]. Weippert M; Anders O; Schmidt M; Roewer J Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823 [TBL] [Abstract][Full Text] [Related]
6. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Lusher JM Ann Hematol; 1991 Sep; 63(3):138-41. PubMed ID: 1932288 [No Abstract] [Full Text] [Related]
7. Treatment of hemophilic patients with factor VIII inhibitor. Abildgaard CF; Britton M Ann N Y Acad Sci; 1975 Jan; 240():400-4. PubMed ID: 1053883 [No Abstract] [Full Text] [Related]
9. Porcine factor VIII therapy in patients with factor VIII inhibitors. Hay C; Lozier JN Adv Exp Med Biol; 1995; 386():143-51. PubMed ID: 8851022 [No Abstract] [Full Text] [Related]
10. Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate. Lusher JM Lancet; 1990 Nov; 336(8725):1249-50. PubMed ID: 1978087 [No Abstract] [Full Text] [Related]
11. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377 [TBL] [Abstract][Full Text] [Related]
13. Highly purified porcine factor VIII in haemophilia A. Hewitt P; Mackie IJ; Machin SJ Lancet; 1982 Mar; 1(8274):741-2. PubMed ID: 6122035 [No Abstract] [Full Text] [Related]
14. Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates. Brettler DB Semin Hematol; 1991 Apr; 28(2 Suppl 1):45-6. PubMed ID: 1908128 [No Abstract] [Full Text] [Related]
15. Development of circulating inhibitor directed against factor VIII in patients with haemophilia-A. Cohn J; Nielsen VG Scand J Haematol; 1972; 9(5):524-30. PubMed ID: 5074558 [No Abstract] [Full Text] [Related]
16. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies. Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234 [No Abstract] [Full Text] [Related]
17. Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors. Wensley RT; Stevens RF; Burn AM; Delamore IW Br Med J; 1980 Nov; 281(6252):1388-9. PubMed ID: 6777018 [TBL] [Abstract][Full Text] [Related]
18. Factor VIII inhibitors in haemophilia. Lancet; 1983 Apr; 1(8327):742-3. PubMed ID: 6132087 [No Abstract] [Full Text] [Related]
19. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia. Zwahlen H; Beck EA Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572 [TBL] [Abstract][Full Text] [Related]